<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cunningham, Muriel</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Hanley, Daniel F.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Update on the MISTIE Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-10</style></pages><abstract><style  face="normal" font="default" size="100%">Intracerebral hemorrhage (ICH) mortality estimates range from 37% (STICH trial) to 56% (SCHIPA trial). The Minimally Invasive Surgery plus t-PA for Intracerebral Hemorrhage Evacuation [MISTIE] trial was a phase 2 study sponsored by the National Institute of Neurological Disease and Stroke. The objective of the study was to determine whether reduction of clot size in ICH leads to lower mortality and better outcomes for patients.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>